Athenex Gets FDA Compounding Policy Wrong, Amicus Says
By Dani Kass · September 21, 2018, 7:49 PM EDT
Compounder Athenex Pharma Solutions LLC is wrongly attempting to broaden a U.S. Food and Drug Administration policy governing bulk compounding, and its "gross misinterpretation" must be kept out of Par Pharmaceutical's...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login